What's Happening?
BioSkryb Genomics, in collaboration with Eremid Genomic Services, has announced the launch of an Early Access Program for its new ResolveSEQ LongRead solution. This program offers researchers access to enhanced single-cell whole-genome long-read sequencing services, providing 75-92% genomic coverage from a single cell. The technology utilizes BioSkryb's Primary Template-directed Amplification (PTA) and Eremid's custom PacBio library preparation, achieving over 70% sensitivity in detecting single-nucleotide variants and complex genomic regions. This advancement is expected to benefit fields such as oncology, neurology, and gene therapy by allowing detailed analysis of complex structural rearrangements and genomic variations.
Why It's Important?
The introduction of the ResolveSEQ LongRead solution marks a significant advancement in genomic research, particularly in single-cell sequencing. By offering greater genomic coverage and sensitivity, this technology addresses limitations of existing methods, enabling more accurate and comprehensive genetic analyses. This can lead to breakthroughs in understanding complex diseases, improving precision medicine, and developing targeted therapies. Researchers in various fields stand to gain from these insights, potentially leading to innovations in treatment strategies and personalized medicine.
What's Next?
Researchers participating in the Early Access Program will be able to explore the capabilities of the ResolveSEQ LongRead solution, potentially leading to new discoveries in genomics. The program may also pave the way for broader adoption of this technology in clinical and research settings. As the technology is further validated, it could become a standard tool in genomic research, influencing future studies and applications in precision medicine.
